20/20 Biolabs (AIDX) vs UL Solutions (ULS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
UL Solutions is the larger company by market cap ($14.67 billion vs $2.2 million), about 6672.0 times the size, while 20/20 Biolabs is growing revenue faster (+16.7% vs +6.4%). UL Solutions pays a dividend yielding 0.78%, while 20/20 Biolabs does not currently pay one. UL Solutions converts more of its revenue into profit, with a net margin of 10.6% versus -182.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIDX | ULS |
|---|---|---|
| Share price | $0.1571 | $72.64 |
| Market cap | $2.20M | $14.67B |
| 1-day change | -13.49% | -2.99% |
| YTD return | — | -7.89% |
| 1-year return | — | -15.24% |
| P/E ratio (TTM) | — | 28.83 |
| Forward P/E | — | 27.49 |
| EPS (TTM) | $-0.75 | $2.52 |
| Dividend yield | 0.00% | 0.78% |
| Annual dividend | $0.00 | $0.565 |
| Revenue (latest FY) | $2.05M | $3.05B |
| Revenue growth (YoY) | +16.71% | +6.38% |
| Net income (latest FY) | $-3.74M | $325.00M |
| Gross margin | 29.56% | 49.46% |
| Operating margin | -162.87% | 17.10% |
| Net margin | -182.82% | 10.65% |
| 52-week high | $50.00 | $107.54 |
| 52-week low | $0.1556 | $63.17 |
| Distance from 52-week high | -99.69% | -32.45% |
| Analyst consensus | none | buy |
| Avg. price target upside | +3082.69% | +32.78% |
| Average volume | 139.24K | 873.95K |
| Shares outstanding | 13.99M | 78.15M |
| Employees | 4 | 14,587 |
| Sector | Health Care | Health Care |
| Industry | Precision Instruments | Precision Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UL Solutions is about 6672.0 times larger than 20/20 Biolabs by market value ($14.67B vs $2.20M).
- UL Solutions is more profitable, keeping 10.6 cents of every revenue dollar as net income versus -182.8 cents for 20/20 Biolabs.
- 20/20 Biolabs grew revenue faster in its latest fiscal year (+16.71% vs +6.38%).
About 20/20 Biolabs
AIDX stock →20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.
Health Care · Precision Instruments · 4 employees
About UL Solutions
ULS stock →UL Solutions Inc., together with its subsidiaries, provides testing, inspection and certification services and related software and advisory services worldwide. It operates through three segments: Industrial, Consumer, and Software and Advisory.
Health Care · Precision Instruments · 14,587 employees
AIDX vs ULS FAQ
Which is bigger, 20/20 Biolabs or UL Solutions?
UL Solutions (ULS) is larger, with a market capitalization of $14.67B compared with $2.20M for 20/20 Biolabs (AIDX).
Which pays a higher dividend, 20/20 Biolabs or UL Solutions?
UL Solutions pays a dividend yielding 0.78%, while 20/20 Biolabs does not currently pay a regular dividend.
Are 20/20 Biolabs and UL Solutions in the same industry?
Yes. Both are classified in the Precision Instruments industry within the Health Care sector.